BioCentury | Jun 17, 2013

Living the dream

PeptiDream Inc. (Tokyo:4587) jumped over 400% in its first week of trading, but due to rules on daily price limits, there's no telling what investors are really willing to pay for the company. The preclinical...
BioCentury | Feb 11, 2013

Bubbling up in Japan

Japan's biotech stocks have benefited from a spike in interest from retail investors driven in part by last October's Nobel Prize for a Kyoto University stem cell researcher. Company executives who spoke with BioCentury are...
BioCentury | Jan 14, 2013

Darwin's delight

The biotech ecosystem looks healthy moving into 2013. With the space above $1 billion more than replenished in 2012, mid-cap names have money to create their own tier-jumping stories this year, while investors see natural...
BC Week In Review | Dec 24, 2012
Financial News

Gene Techno Science completes IPO

Gene Techno Science Co. Ltd. (Tokyo:4584), Sapporo, Japan   Business: Cancer, Autoimmune, Musculoskeletal   Date completed: 11/30/12   Type: IPO   Raised: ¥696 million ($8.4 million)   Shares: 580,000   Price: ¥1,200   Shares after...
BC Week In Review | Jul 9, 2007
Company News

Gene Techno Science, Kaken deal

Gene Techno granted Kaken an exclusive, worldwide license to develop, manufacture and market antibodies that target integrin alpha(9) . The companies will collaborate on preclinical R&D of the antibodies to treat autoimmune and bone diseases. Gene...
Items per page:
1 - 5 of 5